Dyadic to Attend Industry Events in June
Dyadic International (NASDAQ: DYAI), a biotechnology company specializing in large-scale production of proteins for vaccines, therapeutics, and other applications, announced its participation in several industry events in June 2024.
These events include BIO 2024 at the San Diego Convention Center from June 3-6, where Dyadic will present on June 5 at 11:00 AM PT. Additionally, Dyadic will attend the Future Food Tech-Alt Proteins conference in Chicago from June 17-18, and the 2024 NIIMBL National Meeting in Washington, DC from June 25-27.
These appearances are part of Dyadic's strategy to engage with industry stakeholders and showcase their innovations. Meetings can be scheduled with Dyadic's management by contacting Heidi Zosiak.
- Dyadic's participation in key industry events may boost visibility and investor interest.
- The June 5 presentation at BIO 2024 could lead to new partnerships or business opportunities.
- Engagement in conferences like Future Food Tech-Alt Proteins aligns with Dyadic's expansion into non-pharmaceutical markets.
- The press release lacks specific business updates or financial performance data, which may concern investors looking for concrete progress.
- Repeated attendance at events might signal a need for ongoing visibility efforts, potentially reflecting unmet business milestones.
JUPITER, Fla., May 30, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a biotechnology company focused on the efficient large-scale manufacture of proteins for use in human and animal vaccines and therapeutics, as well as non-pharmaceutical applications including food, nutrition, and wellness, today announced that its management will be attending the following industry events during June 2024.
BIO 2024
San Diego Convention Center, San Diego, CA
Jun 3 – 6, 2024
Presentation: Wednesday, June 5, 11:00 AM PT
Future Food Tech-Alt Proteins
Renaissance Chicago Downtown Hotel, Chicago, IL
Jun 17 – 18, 2024
2024 NIIMBL National Meeting
Capital Hilton, Washington, DC
Jun 25 – 27, 2024
If you would like to schedule a meeting with one of our management members at any of these events, please contact Heidi Zosiak at hzosiak@dyadic.com.
About Dyadic International, Inc.
Dyadic International, Inc. is a biotechnology company focused on the efficient large-scale manufacture of proteins for use in human and animal vaccines and therapeutics, as well as non-pharmaceutical applications including food, nutrition, and wellness.
Dyadic’s gene expression and protein production platforms are based on the highly productive and scalable fungus Thermothelomyces heterothallica (formerly Myceliophthora thermophila). Our lead technology, C1-cell protein production platform, is based on an industrially proven microorganism (named C1), which is currently used to speed development, lower production costs, and improve performance of biologic vaccines and drugs at flexible commercial scales for the human and animal health markets. Dyadic has also developed the Dapibus™ filamentous fungal based microbial protein production platform to enable the rapid development and large-scale manufacture of low-cost proteins, metabolites, and other biologic products for use in non-pharmaceutical applications, such as food, nutrition, and wellness.
With a passion to enable our partners and collaborators to develop effective preventative and therapeutic treatments in both developed and emerging countries, Dyadic is building an active pipeline by advancing its proprietary microbial platform technologies, including our lead asset DYAI-100 COVID-19 vaccine candidate, as well as other biologic vaccines, antibodies, and other biological products.
To learn more about Dyadic and our commitment to helping bring vaccines and other biologic products to market faster, in greater volumes and at lower cost, please visit http://www.dyadic.com.
Safe Harbor Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act, including those regarding Dyadic International’s expectations, intentions, strategies, and beliefs pertaining to future events or future financial performance, such as the success of our clinical trial and interest in our protein production platforms, our research projects and third-party collaborations, as well as the availability of necessary funding. Forward-looking statements generally can be identified by use of the words “expect,” “should,” “intend,” “anticipate,” “will,” “project,” “may,” “might,” “potential,” or “continue” and other similar terms or variations of them or similar terminology. Forward-looking statements involve many risks, uncertainties or other factors beyond Dyadic’s control. These factors include, but are not limited to, the following: (i) our history of net losses; (ii) market and regulatory acceptance of our microbial protein production platforms and other technologies; (iii) competition, including from alternative technologies; (iv) the results of nonclinical studies and clinical trials; (v) our capital needs; (vi) changes in global economic and financial conditions; (vii) our reliance on information technology; (viii) our dependence on third parties; (ix) government regulations and environmental, social and governance issues; and (x) intellectual property risks. For a more complete description of the risks that could cause our actual results to differ from our current expectations, please see the section entitled “Risk Factors” in Dyadic’s annual reports on Form 10-K and quarterly reports on Form 10-Q filed with the SEC, as such factors may be updated from time to time in Dyadic’s periodic filings with the SEC, which are accessible on the SEC’s website and at www.dyadic.com. All forward-looking statements speak only as of the date made, and except as required by applicable law, Dyadic assumes no obligation to publicly update any such forward-looking statements for any reason after the date of this press release to conform these statements to actual results or to changes in our expectations.
Contact:
Dyadic International, Inc.
Ping W. Rawson, Chief Financial Officer
Phone: 561-743-8333 Email: ir@dyadic.com
FAQ
What events will Dyadic attend in June 2024?
When is Dyadic presenting at BIO 2024?
How can I schedule a meeting with Dyadic at these events?
What is the significance of Dyadic attending Future Food Tech-Alt Proteins?
